Advanced Life Sciences outlines plans for IPO

Advanced Life Sciences Holdings of Woodridge, Illinois, has outlined plans to go public with an offering of 6.4 million shares at $5 per share. Advanced Life Sciences has been developing drugs for infection, cancer and inflammation. Its lead candidate, cethromycin, is a ketolide antibiotic in late-stage clinical development for the treatment of respiratory tract infections.

- read this press release for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.